Your browser doesn't support javascript.
loading
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.
Lorente, David; Omlin, Aurelius; Zafeiriou, Zafeiris; Nava-Rodrigues, Daniel; Pérez-López, Raquel; Pezaro, Carmel; Mehra, Niven; Sheridan, Elizabeth; Figueiredo, Ines; Riisnaes, Ruth; Miranda, Susana; Crespo, Mateus; Flohr, Penny; Mateo, Joaquín; Altavilla, Amelia; Ferraldeschi, Roberta; Bianchini, Diletta; Attard, Gerhardt; Tunariu, Nina; de Bono, Johann.
Affiliation
  • Lorente D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Omlin A; Oncohematology Department, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Zafeiriou Z; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Nava-Rodrigues D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Pérez-López R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Pezaro C; Eastern Health Medicine School, Monash University, Box Hill, VC, Australia.
  • Mehra N; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Sheridan E; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Figueiredo I; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Riisnaes R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Miranda S; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Crespo M; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Flohr P; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Mateo J; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Altavilla A; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Ferraldeschi R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Bianchini D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Attard G; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Tunariu N; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • de Bono J; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK. Electronic address: johann.de-Bono@icr.ac.uk.
Clin Genitourin Cancer ; 14(6): 485-493, 2016 12.
Article in En | MEDLINE | ID: mdl-27246360
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow / Bone Neoplasms / Prostatic Neoplasms, Castration-Resistant Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans / Male Language: En Journal: Clin Genitourin Cancer Journal subject: NEOPLASIAS / UROLOGIA Year: 2016 Document type: Article Affiliation country: United kingdom Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow / Bone Neoplasms / Prostatic Neoplasms, Castration-Resistant Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans / Male Language: En Journal: Clin Genitourin Cancer Journal subject: NEOPLASIAS / UROLOGIA Year: 2016 Document type: Article Affiliation country: United kingdom Country of publication: United States